Thursday Dec 5
Rheumatism treatment effective even when the use of biological agents is slightly delayed
The immediate use of a biological agent associated with more side effects and higher costs in the treatment of rheumatoid arthritis yields no better results than a less aggressive plan with the delayed use of biological agents where necessary.
The Globe and Mail
Why isn't the 'gold standard' of abortion drugs available in Canada?
In Canada, there are about 100,000 abortions a year, most of them performed surgically in clinics or hospitals.
Usability testing of ANSWER: a web-based methotrexate decision aid...
Decision aids are evidence-based tools designed to inform people of the potential benefit and harm of treatment options, clarify their preferences and provide a shared decision-making structure for discussion at a clinic visit.
Antares Pharma Announces Additional U.S. Patent Protection for OTREXUPa
Antares Pharma, Inc. today announced the issuance of U.S. Patent 8,579,865. This new patent is related to a previously issued U.S. patent 8,480,631, and includes additional claims that describe injection devices for the subcutaneous delivery of methotrexate.
Arthritis drug Sarilumab slows down the condition and improves mobility
Arthritis sufferers have been given new hope following the success of a drug that eases crippling symptoms of the disease.
UPDATE 1-Sanofi, Regeneron arthritis drug meets goals in Phase 3 trial
An experimental drug for rheumatoid arthritis developed by French drugmaker Sanofi and Regeneron, when combined with methotrexate, improved symptoms and physical function and slowed progression of the disease in a late-stage clinical trial.
Pfizer Inc. Wins Final FDA Approval For XELJANZ
Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZA Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis NEW YORK-- -- Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved the supplemental New Drug Application for ... (more)